The US Food and Drug Administration (FDA) has made a groundbreaking decision by approving the over-the-counter use of the oral contraceptive Opill. This marks a significant milestone as Opill becomes the first nonprescription birth control pill available in the United States. However, it is important to note that it will not be available until early 2024.
The American College of Obstetricians and Gynecologists (ACOG) recognizes this approval as a crucial step towards improving accessibility to reproductive health care. By eliminating barriers such as the need for time off work, office visit copays, and prescription refill protocols, Opill aims to provide a more convenient and inclusive option for women seeking birth control.
Opill, often referred to as a “mini-pill,” utilizes progestin, a synthetic form of the hormone progesterone, and does not contain estrogen. Unlike combination birth control pills that incorporate both hormones, Opill solely relies on progestin. When taken as directed, it boasts an effectiveness rate of approximately 98%. However, it does not serve as emergency contraception or abortion medication.
One of the most significant advantages of Opill’s over-the-counter status is its potential to benefit marginalized groups facing obstacles in accessing reproductive health care. Dr. Kristyn Brandi, an ob/gyn in New Jersey, believes that individuals who have experienced racism or transphobia in medicine can benefit greatly from Opill’s availability. Moreover, the absence of an age limit for purchasing Opill can positively impact adolescents and young adults who may lack the resources to access birth control.
Despite its advantages, Opill does come with potential side effects. Dr. Anne-Marie Amies Oelschlager, chair of ACOG’s Clinical Consensus Committee on Gynecology, highlights that irregular bleeding, headaches, dizziness, nausea, increased appetite, abdominal pain, cramps, or bloating may occur. However, progestin-only methods are generally considered safer for individuals with migraine headaches, uncontrolled blood pressure, and those at high risk of blood clots.
While the cost and insurance coverage of Opill are currently unknown, Frederique Welgryn, Perrigo’s global vice president for women’s health, assures that pricing details will be disclosed in the coming months. There is uncertainty regarding whether insurance companies will cover nonprescription contraception. However, there is hope that Opill will be covered by insurers, similar to other prescription birth control products.
The availability and affordability of Opill aim to combat the high number of unintended pregnancies in the United States. Approximately 46% of the 6.1 million annual pregnancies in the country are unintended. It is important to note that there may be legal challenges to Opill’s approval following recent rulings on abortion drugs. Nevertheless, experts believe that this groundbreaking approval will transform the way contraception is perceived and become a normalized part of reproductive health care.
“Zombie enthusiast. Subtly charming travel practitioner. Webaholic. Internet expert.”